SCHEMBL23514874

SCHEMBL23514874

CCC1(O)CCC2(CC1)CC2

nearest known ligand 0.35

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 3/20 0.35
SLC6A3 Q01959 3/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24517845 0.92 SLC6A4 (0.33) SLC6A4SLC6A3
SCHEMBL23514883 0.82 SLC6A4 (0.31) SLC6A4SLC6A3
SCHEMBL30945790 0.79 SLC6A4 (0.34) SLC6A4SLC6A3
SCHEMBL129903 0.78
SCHEMBL1266379 0.77
SCHEMBL128062 0.77 SLC6A4 (0.33) SLC6A4SLC6A3
SCHEMBL355528 0.75 CYP2C19 (0.34) SLC6A4SLC6A3
SCHEMBL6062608 0.75 CYP2C19 (0.34) SLC6A4SLC6A3
SCHEMBL955188 0.75 CYP2C19 (0.34) SLC6A4SLC6A3
SCHEMBL43020 0.75

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250066350-A1 AROMATIC HETEROCYCLE-SUBSTITUTED COMPOUNDS, AND PREPARATION METHOD THEREFOR AND USE THEREOF INNOVSTONE THERAPEUTICS LIMITED (CN) 2025-02-27 US disclosed
WO-2023109883-A1 AROMATIC HETEROCYCLE-SUBSTITUTED COMPOUNDS, AND PREPARATION METHOD THEREFOR AND USE THEREOF 上海翊石医药科技有限公司 2023-06-22 WO disclosed
CN-116262749-A Aromatic heterocycle substituted compound and preparation method and application thereof 上海翊石医药科技有限公司 2023-06-16 CN disclosed
US-20210177856-A1 USE OF ATR INHIBITORS IN COMBINATION WITH PARP INHIBITORS REPARE THERAPEUTICS INC. (CA) 2021-06-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250066350-A1 AROMATIC HETEROCYCLE-SUBSTITUTED COMPOUNDS, AND PREPARATION METHOD THEREFOR AND USE THEREOF ATR, WEE1, WEE2 SLC6A4 2542/4885SLC6A3 3072/4885
US-20210177856-A1 USE OF ATR INHIBITORS IN COMBINATION WITH PARP INHIBITORS ATR, MRE11, PARP2 SLC6A4 4813/4885SLC6A3 4863/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.